Health
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
WASHINGTON, Feb. 25, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...
2024-02-26 02:00
1213
China Medical University Hospital's Breakthrough: Leg Salvage Against Deadly Arterial Disease. Amputation and Death Rates Plunge from 30% to Below 3%
TAICHUNG, Feb. 24, 2024 /PRNewswire/ -- In winter, cardiovascular diseases are more prevalent, which significantly increase the likelihood of arterial blockage. In addition to increasing the possibility of accompanying myocardial infarction or stroke, seniors should be especially cautious about P...
2024-02-24 21:30
2201
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effectiveWednesday, March 6, 2024, with trading to begin on a split-adjusted basi...
2024-02-24 05:05
4003
HeyGears Unveils Automated Case-by-Case Clear Aligner Production Solution
IRVINE, Calif., Feb. 23, 2024 /PRNewswire/ -- HeyGears
2024-02-23 23:00
1687
Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunothera...
2024-02-23 21:00
1830
Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors
- The first EpCAM targeted CAR-T product obtained US/CN IND approval. - Acceptable safety profiles and preliminary efficacy were observed in Investigator-Initiated Trial (IIT) clinical studies of IMC001. SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Immunofoco, a company dedicated to developing cell ...
2024-02-23 12:51
1184
Jolly Good Revolutionizes Healthcare with Immersive Service for Apple Vision Pro, Premiering at SXSW 2024
A Milestone Entry into Spatial Computing Healthcare BROOKLINE, Mass., Feb. 22, 2024 /PRNewswire/ -- Jolly Good US Inc. proudly presents "JOLLYGOOD+ for Vision Pro," a groundbreaking immersive medical service harnessing the power of spatial computing through Apple Vision Pro technology. This inno...
2024-02-23 02:00
1564
CATUG and Crystal Bio Establish Strategic Partnership, Launching "CATUG-Crystal" Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
CAMBRIDGE, Mass. and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) andCrystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services. CATUG, a distinguished global entity specializin...
2024-02-22 21:00
1271
VOCIC Presents its Latest Products at Arab Health 2024 in Dubai
CITY OF INDUSTRY, Calif., Feb. 21, 2024 /PRNewswire/ -- The VOCIC team showcased its latest home medical care and senior care products at Arab Health 2024 in Dubai, held from January 29th to February 1st. The exhibition provided a crucial chance to present VOCIC's innovative healthcare solutions t...
2024-02-21 22:20
1292
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first recorded tria...
2024-02-21 22:00
1390
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
* Named Top-Rated for fourth consecutive year * Committed to generating long-term value for all stakeholders SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has ...
2024-02-21 18:00
2727
Zylox-Tonbridge Receives Marketing Approvals for Multiple Products in the UAE
HANGZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK), a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in theUnited Arab Emirates for five of i...
2024-02-21 16:16
1154
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "Inveni...
2024-02-21 11:56
1192
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors again...
2024-02-20 22:30
1445
FDA Grants Orphan Drug Designation to 9MW3011
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...
2024-02-20 22:00
1301
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Admi...
2024-02-20 22:00
1267
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...
2024-02-20 21:00
2982
Origin Agritech Regains Compliance with Nasdaq Listing Standards
BEIJING, Feb. 20, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that it has regained compliance with Nasdaq's market value of listed securities requirement as set forth in Listing Rule 5550(...
2024-02-20 20:00
2451
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
BEIJING, Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter (the "Letter") from t...
2024-02-20 20:00
2614
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)
HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced th...
2024-02-20 20:00
1173
Week's Top Stories
Most Reposted
Co-creating a Digital and Intelligent World, H3C Digital Tour 2024 Concludes Successfully
[Picked up by 297 media titles]
2024-07-04 12:02
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
[Picked up by 291 media titles]
2024-07-01 09:05
AI and Sustainability in Advanced Manufacturing to take Centre Stage at Industrial Transformation ASIA-PACIFIC (ITAP) 2024
[Picked up by 285 media titles]
2024-07-03 15:51
National Cancer Society Malaysia and Gene Solutions Forge Partnership to Expand Multi-Cancer Early Detection Awareness and Access
[Picked up by 278 media titles]
2024-07-01 12:55
The Global Multimedia Deepfake Detection Challenge 2024 Officially Announced with Over $130,000 in Prizes
[Picked up by 277 media titles]
2024-07-01 16:47
Most Read
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
2024-07-01 09:05
17274
National Cancer Society Malaysia and Gene Solutions Forge Partnership to Expand Multi-Cancer Early Detection Awareness and Access
2024-07-01 12:55
12033
Transforming Healthcare with AI: YiduTech's Gong Rujing at Summer Davos
2024-07-01 10:17
10271
